Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

The HTA perspective: Is tissue-independent approval the next top model?

Date

17 Oct 2020

Session

Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics

Topics

Bioethical Principles and GCP

Tumour Site

Presenters

Sonia Garcia Perez

Authors

S. Garcia Perez

Author affiliations

  • Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), 28022 - Madrid/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.